A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ASCO 2009 Highlights<br />
Avastin<br />
NSABP C-08: Adjuvant col<strong>on</strong> cancer efficacy results – late-breaker abstract<br />
RIBBON-1: 1 st line HER2-negative metastatic breast cancer – oral presentati<strong>on</strong><br />
Tarceva<br />
ATLAS: 1 st line maintenance therapy for advanced n<strong>on</strong>-small cell lung cancer –<br />
late-breaker oral presentati<strong>on</strong><br />
SATURN: 1 st line maintenance therapy for advanced n<strong>on</strong>-small cell lung cancer –<br />
oral presentati<strong>on</strong><br />
SATURN: 1 st line maintenance therapy for advanced n<strong>on</strong>-small cell lung cancer biomarker data<br />
Herceptin<br />
ToGA: 1 st line HER2-positive advanced gastric cancer –<br />
oral presentati<strong>on</strong><br />
T-DM1<br />
Phase II sec<strong>on</strong>d-line+ HER2-positive mBC final results<br />
Joint <strong>Roche</strong>-Genentech<br />
Investor Science Events<br />
Sunday May 31st<br />
NSABP = Nati<strong>on</strong>al Surgical Adjuvant Breast <strong>and</strong> Bowel Project<br />
M<strong>on</strong>day June 1st<br />
25
Change language